Clinical trial · Observational
Metabolomic Analysis of Body Fluid of Medulloblastoma in Children
Metabolomic Analysis of Body Fluid of Medulloblastoma in Children Based on New Mass Spectrometry and Its Application in Clinical Diagnosis and Recurrence Monitoring
NCT04065204CI-TRIAL-00040754unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Based on a new mass spectrometry system, body fluid samples were analyzed to verify the role of metabolite analysis in the diagnosis of pediatric medulloblastoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pediatric Medulloblastoma | Childhood Medulloblastoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Metabolic marker(Uracil in Da)
- timeFrame
- Changes of expression profiles of specific metabolic markers before and after radiotherapy,up to 3 months.
- description
- 1\. By comparing the expression of small molecule metabolites in body fluids between normal control group and patients with medulloblastoma before radiotherapy, to find specific markers. 2. To evaluate the expression of this metabolic marker in medulloblastoma patients before and after radiotherapy.
- measure
- Metabolic marker(4-Hydroxyproline in Da)
- timeFrame
- Changes of expression profiles of specific metabolic markers before and after radiotherapy,up to 3 months.
- description
- 1\. By comparing the expression of small molecule metabolites in body fluids between normal control group and patients with medulloblastoma before radiotherapy, to find specific markers. 2. To evaluate the expression of this metabolic marker in medulloblastoma patients before and after radiotherapy.
- measure
- Metabolic marker(Creatine in Da)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 3 Years
Show eligibility criteria text
Inclusion Criteria: * The samples are previous biological sample database data; * Sample collection time was 2017.05-2019.05; * The patient's age is over 3 years old; * KPS score ≥50 at the first diagnosis; * The patient was a medulloblastoma patient who had received surgical treatment and had not received radiotherapy or chemotherapy before. Exclusion Criteria: * Recurrent patients; * Patients suffered from other malignant tumors during radiotherapy; * The body fluid samples or related clinical data are not perfect; * Storage failure of body fluid samples such as lipid dissolution and hemolysis occurred.
References
Publications (0)
Data not yet available
No reference posted for this study.